Chemical Engineering > Nova Content
Written by Rebecca L. Wright, Ph.D. and Eric Furman, Ph.D.
In an ongoing set of disputes in Oregon between farmers and corporations that hold GMO patents, farmers ... Read More »
Written by Linda Xu and Kerry S. Taylor, Ph.D.
The PTAB issued a Final Written Decision finding that Biogen’s patent on treating Multiple Sclerosis... Read More »
Written by Marc Chatenay-Lapointe, Ph.D. and Jing Liu, Ph.D.
On March 13, 2017, the use of Novartis cell cycle inhibitor Kisqali® (ribociclib, LEE011) in... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Kerry S. Taylor, Ph.D.
Bevacizumab (Avastin®) is the subject of the widely watched “patent dance”... Read More »
Written by Jeffrey C. Wu, Ph.D. and Brenden S. Gingrich, Ph.D.
I. Summary
The Supreme Court in Life Technologies Corp. v. Promega Corp. held that providing a... Read More »
Written by Mark E. Davis and Kerry S. Taylor, Ph.D.
The PTAB issued two final written decisions upholding The University of Pennsylvania’s claims to methods ... Read More »
Written by Sabrina Wang and Adam Powell
The Federal Circuit held that a rat study in a provisional application and a conversion method in an uncited reference did ... Read More »
Written by Scott Siera, Ph.D. and Michael L. Fuller
Obtaining issued patents in the biotechnology space can be a challenge. Here is a list of ten patent... Read More »
Written by Kerry S. Taylor, Ph.D. and Nathanael Luman, Ph.D.
The PTAB issued a Final Written Decision upholding Pozen’s ulcer reducing Vimovo® claims... Read More »
Written by Caleb A. Bates, Ph.D. and Agnes Juang, Ph.D.
On January 12, 2017, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the... Read More »
Written by Hyeongsu Rick Park and Kerry S. Taylor, Ph.D.
The Patent Trial and Appeal Board (PTAB) terminated a patent interference proceeding between the... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Jing Liu, Ph.D.
Once considered parasites, free riders, or “opportunistic pathogens,” in recent years the... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Nathanael R. Luman, Ph.D.
The PTAB denied institution of an IPR based on patent owner’s challenge to the prior art ... Read More »
Written by Daniel A. Kamkar and Eric Furman, Ph.D.
After the United Kingdom voted to leave the European Union, dubbed “Brexit” by the press, many have ... Read More »
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D.
On January 13, 2017, the Supreme Court granted certiorari in Amgen v. Sandoz, 794. f. 3d 1347 (Fed. Cir... Read More »
Written by Paul Chang, Ph.D. and Brenden Gingrich, Ph.D.
Anticipation by inherent disclosure requires that a single prior art reference necessarily includes the... Read More »
Written by Marc Chatenay-Lapointe, Ph.D. and Michael L. Fuller
On December 23, 2016, the U.S. Food and Drug Administration approved SPINRAZA™ (nusinersen)... Read More »
Written by Scott Siera, Ph.D. and Agnes Juang, Ph.D.
Patent applications containing nucleic acid or protein sequences are required to include an electronic... Read More »
A unique public-private partnership provides medical research centers and the patents they generate with a more efficient and rewarding path toward... Read More »
Written by Agnes Juang, Ph.D. and Scott Siera, Ph.D.
Once a European patent application has been granted, all patentees must then choose to validate the granted... Read More »